A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer

Nature Genetics

Volumn 42, Issue 5, 2010, Pages 415-419

  Kiemeney, Lambertus A ^a,b,c   Sulem, Patrick ^d   Besenbacher, Soren ^d   Vermeulen, Sita H ^a   Sigurdsson, Asgeir ^d   Thorleifsson, Gudmar ^d   Gudbjartsson, Daniel F ^d   Stacey, Simon N ^d   Gudmundsson, Julius ^d   Zanon, Carlo ^d   Kostic, Jelena ^d   Masson, Gisli ^d   Bjarnason, Hjordis ^d   Palsson, Stefan T ^d   Skarphedinsson, Oskar B ^d   Gudjonsson, Sigurjon A ^d   Witjes, J Alfred ^b   Grotenhuis, Anne J ^a   Verhaegh, Gerald W ^b   Bishop, D Timothy ^e   Sak, Sei Chung ^f   Choudhury, Ananya ^g   Elliott, Faye ^e   Barrett, Jennifer H ^e   Hurst, Carolyn D ^f   De Verdier, Petra J ^h   Ryk, Charlotta ^h   Rudnai, Peter ⁱ   Gurzau, Eugene ^j   Koppova, Kvetoslava ^k   Vineis, Paolo ^l,m   Polidoro, Silvia ^l,n   Guarrera, Simonetta ^l,n   Sacerdote, Carlotta ^n,o   Campagna, Marcello ^p   Placidi, Donatella ^p   Arici, Cecilia ^p   Zeegers, Maurice P ^q,r   Kellen, Eliane ^s   Gutierrez, Berta Saez ^t   Sanz Velez, José I ^u   Sanchez Zalabardo, Manuel ^v   Valdivia, Gabriel ^t   Garcia Prats, Maria D ^u   Hengstler, Jan G ^w   Blaszkewicz, Meinolf ^w   Dietrich, Holger ^x   Ophoff, Roel A ^y,z   Van Den Berg, Leonard H ^y   Alexiusdottir, Kristin ^aa   Kristjansson, Kristleifur ^d   Geirsson, Gudmundur ^aa   Nikulasson, Sigfus ^ab   Petursdottir, Vigdis ^ab   Kong, Augustine ^d   Thorgeirsson, Thorgeir ^d   Mungan, N Aydin ^ac   Lindblom, Annika ^h   Van Es, Michael A ^y   Porru, Stefano ^p   Buntinx, Frank ^s,ad   Golka, Klaus ^w   Mayordomo, José I ^t   Kumar, Rajiv ^ae   Matullo, Giuseppe ^l,n   Steineck, Gunnar ^h,af   Kiltie, Anne E ^ag   Aben, Katja K H ^a,c   Jonsson, Eirikur ^aa   Thorsteinsdottir, Unnur ^d,ah   Knowles, Margaret A ^f   Rafnar, Thorunn ^d   Stefansson, Kari ^d,ah   more..

^a Department of Epidemiology Biostatistics and Health Technology Assessment   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Integraal Kankercentrum Oost   (Netherlands)

^d DECODE GENETICS   (Iceland)

^e Section of Epidemiology and Biostatistics   (United States)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH   (Hungary)

^j Environmental Health Center   (Romania)

^k State Health Institute   (Slovakia)

^l ISI FOUNDATION   (Italy)

^m IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁿ UNIVERSITY OF TURIN   (Italy)

^o Center for Cancer Prevention CPO Piemonte   (Italy)

^p UNIVERSITY OF BRESCIA   (Italy)

^q UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^r MAASTRICHT UNIVERSITY   (Netherlands)

^s UNIVERSITY OF LEUVEN   (Belgium)

^t UNIVERSITY OF ZARAGOZA   (Spain)

^u HOSPITAL SAN JORGE   (Spain)

^v HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^w LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^x Paul Gerhardt Foundation   (Germany)

^y UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa Center for Neurobehavioral Genetics ^*  (United States)

^ab LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^ac ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^ad MAASTRICHT UNIVERSITY   (Netherlands)

^ae GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^af SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^ag UNIVERSITY OF OXFORD   (United Kingdom)

^ah UNIVERSITY OF ICELAND   (Iceland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ALLELE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CHROMOSOME 4P; CONTROLLED STUDY; GENETIC VARIABILITY; HUMAN; ICELAND; INTRON; MAJOR CLINICAL STUDY; NETHERLANDS; PRIORITY JOURNAL; SOMATIC MUTATION;

ALLELES; CHROMOSOMES, HUMAN, PAIR 4; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MODELS, GENETIC; MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECURRENCE; RISK; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 77951769462     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.558     Document Type: Article

References (28)

1. Parkin, D.M. The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl. 12-20 (2008).
2. Knowles, M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27, 361-373 (2006). (Pubitemid 43372866)
3. Murta-Nascimento, C. et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol. Biomarkers Prev. 16, 1595-1600 (2007). (Pubitemid 47294824)
4. Aben, K.K. et al. Familial aggregation of urothelial cell carcinoma. Int. J. Cancer 98, 274-278 (2002).
5. Kiemeney, L.A. et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet. 40, 1307-1312 (2008).
6. Wu, X. et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat. Genet. 41, 991-995 (2009).
7. Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221-227 (2009).
8. Mostof, F.K. Histological Typing of Urinary Bladder Tumours (World Health Organization, Geneva, 1973).
9. Union Internationale Contre le Cancer (UICC). Bladder. in TNM Classifcation of Malignant Tumors 3rd edn. 113-117 (UICC, Geneva, 1978).
10. Billerey, C. et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955-1959 (2001). (Pubitemid 32545179)
11. Hernandez, S. et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 24, 3664-3671 (2006). (Pubitemid 46630542)
12. Thorgeirsson, T.E. et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638-642 (2008).
13. Bakkar, A.A. et al. Occupational exposure to polycyclic aromatic hydrocarbons infuenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. Mol. Carcinog. 49, 25-31 (2010).
14. Wallerand, H. et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are infuenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis 26, 177-184 (2005). (Pubitemid 40207713)
15. Kong, A. et al. Detection of sharing by descent, long-range phasing and haplotype imputation. Nat. Genet. 40, 1068-1075 (2008).
16. Kong, A. et al. Parental origin of sequence variants associated with complex diseases. Nature 462, 868-874 (2009).
17. Tomlinson, D.C., L'Hote, C.G., Kennedy, W., Pitt, E. & Knowles, M.A. Alternative splicing of fbroblast growth factor receptor 3 produces a secreted isoform that inhibits fbroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res. 65, 10441-10449 (2005). (Pubitemid 41743738)
18. Emilsson, V. et al. Genetics of gene expression and its effect on disease. Nature 452, 423-428 (2008). (Pubitemid 351450845)
19. Tomlinson, D.C., Baldo, O., Harnden, P. & Knowles, M.A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213, 91-98 (2007). (Pubitemid 47354570)
20. Cappellen, D. et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20 (1999).
21. Catto, J.W. et al. Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer Res. 69, 8472-8481 (2009).
22. Gretarsdottir, S. et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat. Genet. 35, 131-138 (2003). (Pubitemid 37187631)
23. Falk, C.T. & Rubinstein, P. Haplotype relative risks: an easy reliable way to construct a proper control sample for risk calculations. Ann. Hum. Genet. 51, 227-233 (1987). (Pubitemid 17121184)
24. Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719-748 (1959).
25. Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55, 997-1004 (1999).
26. Stefansson, H. et al. A common inversion under selection in Europeans. Nat. Genet. 37, 129-137 (2005).
27. Epstein, J.I., Amin, M.B., Reuter, V.R. & Mostof, F.K. The World Health Organization/International Society of Urological Pathology consensus classifcation of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol. 22, 1435-1448 (1998).
28. van Oers, J.M. et al. A simple and fast method for the simultaneous detection of nine fbroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin. Cancer Res. 11, 7743-7748 (2005).